News and Announcements
SUDA granted meeting with UK MHRA for approval of ZolpiMist™
- Published May 25, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted SUDA a meeting on 21 June 2017 to discuss the proposed plan for registration of SUDA’s novel ZolpiMist™ oral spray of zolpidem tartrate to treat insomnia in the UK and European Union.
KEY TAKEAWAYS:
- SUDA is seeking advice on the suitability of its regulatory strategy which is to file for approval of ZolpiMist in Europe based on the data that successfully resulted in the product’s US FDA approval.
- The proposed regulatory dossier is intended to support a marketing authorisation application to either the MHRA or the European Medicines Agency.
- SUDA will be seeking advice from the MHRA on the acceptability of the excipients used in the ZolpiMist oral spray formulation which are all listed in the US pharmacopeia.
Mr Stephen Carter, SUDA’s CEO and Managing Director, commented: “It is estimated that about 100 million people suffer from some sort of insomnia in the EU (source: EFPIA). There remains a significant unmet need for new treatment options, particularly for patients that want rapid onset of sleep, have problems swallowing tablets or have gastrointestinal complications. For these patients, ZolpiMist offers an attractive alternative with rapid absorption of the drug through the oral mucosa. We look forward to the feedback from the MHRA and to bringing ZolpiMist to market in this key territory.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
